Latest News

KlikDokter in Partnership with the Indonesian Ministry of Health and BNPB: Conducting Rapid Test for COVID-19

KlikDokter in Partnership with the Indonesian Ministry of Health and BNPB: Conducting Rapid Test for COVID-19

Press Release No. 014/KFCP-DIR/PR/IV/20

Jakarta, April 18, 2020, PT Kalbe Farma Tbk (Kalbe) through its subsidiary KlikDokter conducted a risk assessment service in the form of a mass rapid test to reduce the rate of corona virus spread and expediting treatment for communities at risk of COVID-19 exposure. KlikDokter as an integrated digital health service platform has been appointed by the government through the Ministry of Health (Kemenkes) and the National Disaster Management Agency (BNPB) to assist the government in accelerating the handling and management of COVID-19. The mass rapid test was implemented in collaboration with a number of hospitals that followed the Medical Compliance standard to be the location of this rapid test. This rapid test service takes effect from April 21, 2020, and is carried out at partner hospitals that have been designated by KlikDokter according to the hospitals’ operating hours. 

“KlikDokter is committed in helping the community to early detection by conducting initial screening that is accurate, safe, fast, easy, and in line with the government’s call for physical distancing to ensure the safety and security of the community and our partners,” said Dino Bramanto, Director of KlikDokter. “We would like to thank our partner hospitals that helped KlikDokter in realizing the commitment of COVID-19 countermeasures,” Dino added. 

In conducting the mass rapid test, KlikDokter is collaborating with a number of hospitals that followed the Medical Compliance standards to be the location of this rapid test. That way, this risk assessment feature service can cover a variety of communities, especially those who have a high risk of transmitting the COVID-19 virus. The hospitals that collaborate with KlikDokter in the implementation of the rapid test are EMC Tangerang Hospital, EMC Sentul Hospital, Azra Bogor Hospital, Husada Utama Hospital Surabaya and Mitra Keluarga Kelapa Gading Hospital. 

Currently rapid test services are available for KlikDokter customers and the general public in the Greater Jakarta and Surabaya areas and will continue to be expanded to various regions along with the Ministry of Health, BNPB and the government in tackling the spread of the COVID-19 virus. This service is free of charge and applies for 1 free test using the Rapid Test Kits. Customers are only charged the cost of replacing the medical professionals’ personal protective equipment and doctor services. The rapid test services take place in partner hospitals that has been assigned by KlikDokter during the hospitals’ respective operational hours. Registration and administrative payments are made through the KlikDokter application in accordance with applicable terms and conditions. 

“KlikDokter also encourages people not to be afraid and ashamed to check themselves, if they have symptoms and have been in contact with other people or have just traveled from a country that is also infected with COVID-19. The sooner it is detected and the faster the treatment is started, the greater the chance for recovery. 

The process of the service is also very simple, people who want to do a quick test can simply click the Corona Risk Check Ads banner within the KlikDokter application, choose one of the hospitals that has been designated as a partner of KlikDokter, and then make an online appointment and consultation with the doctor who are registered in accordance with government recommendations. If the condition of the user who has followed the rapid test requires further examination, they will get a consultation with the trusted doctors and have collaborated with KlikDokter to assist the patient in getting the appropriate treatment. 

The Rapid Test method use blood samples to be tested. The blood samples will then be used to detect immunoglobulin, an antibody formed when the body has an infection. Thus patients who are already in the early stages of infection can be more quickly identified and addressed. 

This rapid test is supplementing the digital services KlikDokter who has previously launched the Covid-19 risk inspection feature. Through this feature, the public can check the symptoms that are related to COVID-19 before going to the hospital. This feature can be accessed via https://www. 

KLIKDOKTER at a glance
KlikDokter is a digital health platform that has been established since 2008 through a joint venture with PT Elang Mahkota Teknologi Tbk (Emtek) in 2016. Since its inception, KlikDokter has had the spirit of CIE (Communication, Information and Education) with the aim of advancing the health of the Indonesian people. KlikDokter comes with health information that focuses on accuracy and updates from trusted sources. Furthermore, a variety of features around health services - such as 24-hour online consultations, health tools, hospital directories, online drug recommendations, drug delivery and also real-time online booking features and other health features, can be obtained either through website or the KlikDokter application. 

Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Hemapo, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); as well as energy and ready-to-consume drinks (Extra Joss, Hydro Coco); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has approximately 40 subsidiaries and 12 production facilities with international standard, and employs approximately 17,000 employees dispersed across more than 76 branches throughout Indonesia. From 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF). 


465 Rate this article:
No rating

Please login or register to post comments.